Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-29T08:51:48.085Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of Clinical Severity Score Indices for Clostridium difficile Infection

Published online by Cambridge University Press:  02 January 2015

Shigeki Fujitani ,
W. Lance George  and
A. Rekha Murthy
Shigeki Fujitani*
Affiliation:
Division of Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, California Department of Emergency and Critical Care Medicine, St. Marianna University Hospital, Kawasaki, Japan
W. Lance George
Affiliation:
Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, California University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
A. Rekha Murthy
Affiliation:
University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California Department of Hospital Epidemiology, Division of Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, California
*
St. Marianna University Hospital, 2-16-1 Sugao Miyamae-ku, Kawasaki-city, Kanagawa, Japan2168511 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To compare 8 severity score indices for Clostridium difficile infection (CDI).

Design.

Prospective observational study.

Methods.

This study was conducted from July through October 2006. All hospitalized patients in 3 university-affiliated hospitals with a positive fecal Clostridium difficile toxin assay result were evaluated. Infection was considered severe if patients had at least 1 of the following clinical events during their hospitalization: (1) death attributed to CDI within 30 days after diagnosis, (2) colectomy necessitated by CDI, or (3) intensive care unit admission for management of complications attributed to CDI. Severity was assessed on the basis of 8 severity score indices, using published criteria for severe CDI as the benchmark. The 8 severity score indices studied were Beth Israel, University of Pittsburgh Medical Center version 1, University of Pittsburgh Medical Center version 2, Hines VA, modified University of Illinois, University of Calgary version 1, University of Calgary version 2, and University of Temple.

Results.

Of 184 patients with CDI evaluated, 19 had severe cases and 165 had nonsevere cases, as assessed on the basis of the defined severe CDI criteria. Sensitivities of the 8 severity score indices studied ranged from 63.2% to 84.2%, and specificities ranged from 59.4% to 93.9%. The Hines VA index had the highest kappa score (0.69 [95% confidence interval, 0.54-0.83]), followed by the University of Pittsburgh Medical Center version 1 index. Independent risk factors for severe CDI determined by multivariate analysis were abdominal distention (P = .007), fever (temperature, 38.0°C or above; P = .042), white blood cell count of at least 20,000 cells/mm3 (P = .035), and hypoalbuminemia (serum albumin level less than 3 mg/dL; P = .029).

Conclusion.

The Hines VA CDI severity score index appeared to display the strongest correlation for predicting more severe forms of CDI.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 3 , March 2011 , pp. 220 - 228
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Barbut, F, Corthier, G, Charpak, Y, et al.Prevalence and pathogenicity of Clostridium difficile in hospitalized patients: a French multicenter study. Arch Intern Med 1996;156:1449–1454.Google Scholar
2.Bartlett, JG. Clostridium difficile, history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;18(suppl 4):S265–S272.Google Scholar
3.Pepin, J, Valiquette, L, Alary, ME, et al.Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466–472.Google Scholar
4.McDonald, LC, Killgore, GE, Thompson, A, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.Google Scholar
5.Warny, M, Pepin, J, Fang, A, et al.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079–1084.Google Scholar
6.Rubin, MS, Bodenstein, LE, Kent, KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350–354.Google Scholar
7.Loo, VG, Poirier, L, Miller, MA, et al.A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.Google Scholar
8.Redelings, MD, Sondilo, F, Mascola, L. Increase in Clostridium difficile-rehted mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13:1417–1419.CrossRefGoogle ScholarPubMed
9.University of Pittsburgh Medical Center. Guide to Antimicrobial Chemotherapy. 4th ed. 2008. http://www.residency.dom.pitt.edu/Hcorner/Documents/AntimicrobialGuide2008.pdf. Accessed December 20, 2009.Google Scholar
10.Belmares, J, Gerding, DN, Parada, JP, Miskevics, S, Weaver, F, Johnson, S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007;55:495–501.CrossRefGoogle ScholarPubMed
11.Gujja, D, Friedenberg, FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009;29:635–642.Google Scholar
12.Louie, T, Gerson, M, Grimard, D. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2007. Abstract K-425a.Google Scholar
13.Louie, TJ, Peppe, J, Watt, CK, et al.Tolevamer, a novel non-antibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411–420.CrossRefGoogle Scholar
14.McEUistrem, MC, Carman, RJ, Gerding, DN, Genheimer, CW, Zheng, L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40:265–272.Google Scholar
15.Zar, FA, Bakkanagari, SR, Moorthi, KM, Davis, MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.CrossRefGoogle ScholarPubMed
16.Katz, DA, Lynch, ME, Littenberg, B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996;100:487–495.Google Scholar
17.McDonald, LC, Coignard, B, Dubberke, E, Song, X, Horan, T, Kutty, PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.Google Scholar
18.Muto, CA. Clostridium difficile: changes in epidemiology, virulence and outcomes from reemerging pathogen. Self-study audio program. Haddon Heights, NJ: Robert Michael Educational Institute, 2005.Google Scholar
19.Lamontagne, F, Labbe, AC, Haeck, O, et al.Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267–272.CrossRefGoogle ScholarPubMed
20.Henrich, TJ, Krakower, D, Bitton, A, Yokoe, DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009;15:415–422.Google Scholar